CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Karessa Pharma Holding AB (publ) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Karessa Pharma Holding AB (publ)
Lahallsvagen 48
Phone: +46 87682233p:+46 87682233 Taby, 183 30  Sweden
This company was Merged or Acquired on 3/6/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Karessa Pharma Holding AB (publ) is a Sweden-based pharmaceutical company with the goal of developing products based on a patented drug delivery platform with direct absorption of active substances from the oral cavity to the bloodstream. The drug delivery platform is in the form of buccal film, an alignate-based polymer film, which is applied to the oral mucosa and through it the drug is then rapidly delivered into the bloodstream, while the film dissolves without leaving any residues in the mouth. The Company's research and development projects are based on active substances that have already been approved for use as medicinal products in other forms, and include, among others, Karessa k03 vardenafil via buccal film for the treatment of erectile dysfunction and Karessa k21 midazolam via buccal film for the treatment of anxiety and epilepsy symptoms.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201912/31/2018Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board FredrikHubinette 8/22/2019 8/22/2019
Chief Executive Officer MatsNilsson 72 6/18/2018 6/18/2018
Interim Chief Financial Officer BjornPetersson 58 3/21/2018 3/21/2018
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 3 (As of 12/31/2018)
Outstanding Shares: 11,000,000 (As of 9/30/2019)
Stock Exchange: STO


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023